Gilead Sciences Inc (GILD)

$130.86 -0.90 (-0.68%)
Market Cap 162.83B
Revenue (ttm) 29.44B
Net Income (ttm) 8.51B
EPS (ttm) N/A
PE Ratio 15.67
Forward PE N/A
Profit Margin 28.90%
Debt to Equity Ratio 0.95
Volume 8,381,000
Avg Vol 8,117,602
Day's Range N/A - N/A
Shares Out 1.24B
Stochastic %K 37%
Beta 0.32
Analysts Strong Sell
Price Target $158.03

Company Profile

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 650 574 3000
Fax: 650 522 5853
Address:
333 Lakeside Drive, Foster City, United States
imjustjimmymoore
imjustjimmymoore Aug. 5 at 11:29 PM
$CAPR $GILD $XRP.X $BTC.X $LMT http://GitHub.com/jimmymoore888/stet
1 · Reply
Quantumup
Quantumup Aug. 5 at 8:22 PM
Stifel🏁 $LYEL Buy; PT $36 and said -- We believe Rondecabtagene autoleucel (Ronde-cel) is a best-in-class, dual-targeting CD19/CD20 autologous CAR T-cell therapy yielding improved clinical outcomes vs. standard-of-care CD19-targeting CAR T-cell therapy in relapsed/refractory DLBCL. $GILD ACLX IOVA $LEGN NVS ALLO AUTL Here's what else Stifel said in its initiation report: https://x.com/Quantumup1/status/2085098840516870341?s=20
1 · Reply
FibQuants
FibQuants Aug. 5 at 5:53 PM
$GILD is showing strong momentum in HIV prevention. Yeztugo’s launch is driving major revenue growth, and early user retention looks encouraging. The market will be watching whether this adoption can stay durable over time.
0 · Reply
Estimize
Estimize Aug. 5 at 5:03 PM
$GILD reported -6.75 EPS and 7,803 revenue for Q2. http://www.estimize.com/intro/gild?chart=historical&metric_name=eps&utm_content=GILD&utm
0 · Reply
ShinnosukeNohara
ShinnosukeNohara Aug. 5 at 4:16 PM
$GILD shorties destroy it pls🙂
0 · Reply
PFElinepfrenzy1990
PFElinepfrenzy1990 Aug. 5 at 3:56 PM
$GILD - Praise ben’t
0 · Reply
shoagh12
shoagh12 Aug. 5 at 3:48 PM
$GILD
0 · Reply
GreenEnergy7B
GreenEnergy7B Aug. 5 at 3:15 PM
$ALT GLP1 Glucagon is a hot topic these days Jefferies: - "AUD crown with strongest-ever efficiacy" - " Pemvi exceeded our phs2 bull case" - "Delivering best in class AUD efficiacy" Best strategic fit would be: $NVO $PFE $SNY $GILD
0 · Reply
Snptrader
Snptrader Aug. 5 at 2:16 PM
$CMMB starting to trade like we may have another player interested here. $GILD is that you?
0 · Reply
DefenseMania
DefenseMania Aug. 5 at 1:44 PM
$AMGN $GILD $KTOS 😉💰💰💰
1 · Reply
Latest News on GILD
Gilead files automatic mixed securities shelf

2026-08-06T21:10:59.000Z - 2 hours ago

Gilead files automatic mixed securities shelf

Gilead price target lowered to $150 from $156 at Truist

2026-08-05T14:08:38.000Z - 1 day ago

Gilead price target lowered to $150 from $156 at Truist

Gilead price target raised to $123 from $120 at RBC Capital

2026-08-05T11:46:58.000Z - 1 day ago

Gilead price target raised to $123 from $120 at RBC Capital

CORRECTING and REPLACING Gilead Sciences Announces Second Quarter 2026 Financial Results

Aug 4, 2026, 9:41 PM EDT - 1 day ago

CORRECTING and REPLACING Gilead Sciences Announces Second Quarter 2026 Financial Results

AHF Crowns Gilead Corporate Welfare King

Aug 4, 2026, 5:07 PM EDT - 2 days ago

AHF Crowns Gilead Corporate Welfare King

Gilead Sciences Swings to Loss on R&D Costs as HIV-Drug Sales Lift Revenue

Aug 4, 2026, 4:31 PM EDT - 2 days ago

Gilead Sciences Swings to Loss on R&D Costs as HIV-Drug Sales Lift Revenue

Gilead Sciences Earnings Call Transcript: Q2 2026

Aug 4, 2026, 4:30 PM EDT - 2 days ago

Gilead Sciences Earnings Call Transcript: Q2 2026

Gilead Sciences Earnings release: Q2 2026

Aug 4, 2026, 4:30 PM EDT - 2 days ago

Gilead Sciences Earnings release: Q2 2026

Gilead Sciences Slides: Q2 2026

Aug 4, 2026, 4:30 PM EDT - 2 days ago

Gilead Sciences Slides: Q2 2026

Gilead Sciences Quarterly report: Q2 2026

Aug 4, 2026, 4:30 PM EDT - 2 days ago

Gilead Sciences Quarterly report: Q2 2026

Gilead reports Q2 adjusted EPS ($6.75), consensus ($7.25)

2026-08-04T20:07:05.000Z - 2 days ago

Gilead reports Q2 adjusted EPS ($6.75), consensus ($7.25)

Gilead second-quarter sales rise 8%, beating Wall Street estimates

Aug 4, 2026, 4:04 PM EDT - 2 days ago

Gilead second-quarter sales rise 8%, beating Wall Street estimates

Gilead Sciences Announces Second Quarter 2026 Financial Results

Aug 4, 2026, 4:01 PM EDT - 2 days ago

Gilead Sciences Announces Second Quarter 2026 Financial Results

Gilead update on California ruling removes an overhang, says UBS

2026-08-03T19:35:22.000Z - 3 days ago

Gilead update on California ruling removes an overhang, says UBS

California's highest court rules for Gilead, says drugmakers don't have 'duty to innovate'

Aug 3, 2026, 2:52 PM EDT - 3 days ago

California's highest court rules for Gilead, says drugmakers don't have 'duty to innovate'

California's highest court rules for Gilead in 'duty to innovate' case

Aug 3, 2026, 1:04 PM EDT - 3 days ago

California's highest court rules for Gilead in 'duty to innovate' case

Gilead price target lowered to $145 from $155 at Barclays

2026-07-29T09:10:40.000Z - 8 days ago

Gilead price target lowered to $145 from $155 at Barclays

Gilead price target lowered to $165 from $166 at Morgan Stanley

2026-07-27T12:10:54.000Z - 10 days ago

Gilead price target lowered to $165 from $166 at Morgan Stanley

Gilead’s Trodelvy plus Merck’s Keytruda recommended by CHMP in breast cancer

2026-07-24T10:36:10.000Z - 13 days ago

Gilead’s Trodelvy plus Merck’s Keytruda recommended by CHMP in breast cancer

MRK

CHMP Recommends Gilead's Trodelvy® Plus Keytruda® in PD-(L)1-Positive First-Line Metastatic Triple-Negative Breast Cancer

Jul 24, 2026, 6:26 AM EDT - 13 days ago

CHMP Recommends Gilead's Trodelvy® Plus Keytruda® in PD-(L)1-Positive First-Line Metastatic Triple-Negative Breast Cancer

Gilead Sciences to Release Second Quarter 2026 Financial Results on Tuesday, August 4, 2026

Jul 21, 2026, 4:05 PM EDT - 16 days ago

Gilead Sciences to Release Second Quarter 2026 Financial Results on Tuesday, August 4, 2026

Gilead, Merck weekly HIV pill keeps virus suppressed in late-stage trials

Jul 21, 2026, 1:27 PM EDT - 16 days ago

Gilead, Merck weekly HIV pill keeps virus suppressed in late-stage trials

MRK

Gilead to present new HIV research at AIDS 2026

2026-07-21T14:10:37.000Z - 16 days ago

Gilead to present new HIV research at AIDS 2026

Gilead, Merck report ‘high’ rates of virologic suppression in ISLEND trials

2026-07-21T14:05:24.000Z - 16 days ago

Gilead, Merck report ‘high’ rates of virologic suppression in ISLEND trials

MRK

Gilead to Present New HIV Research at AIDS 2026 Across Prevention, Treatment and Cure

Jul 21, 2026, 10:00 AM EDT - 16 days ago

Gilead to Present New HIV Research at AIDS 2026 Across Prevention, Treatment and Cure

Investigational Once-Weekly Oral HIV Treatment Regimen of Islatravir and Lenacapavir Maintained Virological Suppression in Adults With HIV Who Switched Antiretroviral Therapy

Jul 21, 2026, 10:00 AM EDT - 16 days ago

Investigational Once-Weekly Oral HIV Treatment Regimen of Islatravir and Lenacapavir Maintained Virological Suppression in Adults With HIV Who Switched Antiretroviral Therapy

MRK

Gilead downgraded at Leerink on long-term headwinds to HIV PrEP expansion

2026-07-20T20:25:47.000Z - 17 days ago

Gilead downgraded at Leerink on long-term headwinds to HIV PrEP expansion

Gilead downgraded to Market Perform from Outperform at Leerink

2026-07-20T20:20:28.000Z - 17 days ago

Gilead downgraded to Market Perform from Outperform at Leerink

Congo begins trial of Gilead's experimental antiviral for Ebola Bundibugyo

Jul 14, 2026, 8:48 AM EDT - 23 days ago

Congo begins trial of Gilead's experimental antiviral for Ebola Bundibugyo

Gilead price target lowered to $166 from $168 at Morgan Stanley

2026-07-08T11:40:35.000Z - 4 weeks ago

Gilead price target lowered to $166 from $168 at Morgan Stanley

Gilead price target lowered to $156 from $157 at Truist

2026-07-07T13:16:30.000Z - 4 weeks ago

Gilead price target lowered to $156 from $157 at Truist

Gilead price target lowered to $120 from $122 at RBC Capital

2026-07-07T11:26:01.000Z - 4 weeks ago

Gilead price target lowered to $120 from $122 at RBC Capital

U.S. FDA Approves Trodelvy® for First-Line Treatment of Metastatic Triple-Negative Breast Cancer

Jun 24, 2026, 4:29 PM EDT - 6 weeks ago

U.S. FDA Approves Trodelvy® for First-Line Treatment of Metastatic Triple-Negative Breast Cancer

For decades, the only first treatment for one of the deadliest breast cancers was standard chemotherapy. Now there are two newly approved drugs.

Jun 24, 2026, 3:42 PM EDT - 6 weeks ago

For decades, the only first treatment for one of the deadliest breast cancers was standard chemotherapy. Now there are two newly approved drugs.

AZN

European Commission Approves Trodelvy® as a First-Line Treatment for Metastatic Triple-Negative Breast Cancer Patients Not Candidates for PD-(l)1 Inhibitors

Jun 23, 2026, 7:45 AM EDT - 6 weeks ago

European Commission Approves Trodelvy® as a First-Line Treatment for Metastatic Triple-Negative Breast Cancer Patients Not Candidates for PD-(l)1 Inhibitors

The Healthcare M&A Wave

Jun 17, 2026, 12:30 PM EDT - 7 weeks ago

The Healthcare M&A Wave

ABT ALNY AMGN AMRX ANTX AZN BDX

U.S. FDA Accepts Gilead's Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV Prevention

Jun 15, 2026, 4:34 PM EDT - 7 weeks ago

U.S. FDA Accepts Gilead's Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV Prevention

Gilead Mobilizes Rapid Donation of Remdesivir to Support Ebola Response, Building on Decade-Long Commitment to Outbreak Relief

Jun 12, 2026, 8:30 AM EDT - 7 weeks ago

Gilead Mobilizes Rapid Donation of Remdesivir to Support Ebola Response, Building on Decade-Long Commitment to Outbreak Relief

National AIDS Memorial and the Gilead Foundation Launch Major Investment to Expand HIV/AIDS Education and Community Leadership

Jun 11, 2026, 8:30 AM EDT - 2 months ago

National AIDS Memorial and the Gilead Foundation Launch Major Investment to Expand HIV/AIDS Education and Community Leadership

Healthcare ETFs: From Broad Exposure to Big Breakthroughs

Jun 11, 2026, 7:14 AM EDT - 2 months ago

Healthcare ETFs: From Broad Exposure to Big Breakthroughs

ABBV ALKS AMGN IBB IHE JNJ KYMR

Gilead Sciences Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 9, 2026, 1:20 PM EDT - 2 months ago

Gilead Sciences Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Gilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatment

Jun 8, 2026, 4:35 PM EDT - 2 months ago

Gilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatment

MRK

Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study

Jun 8, 2026, 4:30 PM EDT - 2 months ago

Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study

MRK

Gilead Applauds Collaborative Efforts to Launch Lenacapavir for HIV Prevention in South Africa

Jun 5, 2026, 3:00 AM EDT - 2 months ago

Gilead Applauds Collaborative Efforts to Launch Lenacapavir for HIV Prevention in South Africa

Gilead Sciences and Lakefront Complete Acquisition of Ouro Medicines to Further Expand Inflammation Pipeline

Jun 4, 2026, 4:15 PM EDT - 2 months ago

Gilead Sciences and Lakefront Complete Acquisition of Ouro Medicines to Further Expand Inflammation Pipeline

GILEAD SCIENCES AND LAKEFRONT COMPLETE ACQUISITION OF OURO MEDICINES TO FURTHER EXPAND INFLAMMATION PIPELINE

Jun 4, 2026, 4:15 PM EDT - 2 months ago

GILEAD SCIENCES AND LAKEFRONT COMPLETE ACQUISITION OF OURO MEDICINES TO FURTHER EXPAND INFLAMMATION PIPELINE

Gilead's Livdelzi® (Seladelpar) Delivers Statistically Significant Composite ALP Normalization in Phase 3 IDEAL Trial in Primary Biliary Cholangitis (PBC)

Jun 2, 2026, 8:30 AM EDT - 2 months ago

Gilead's Livdelzi® (Seladelpar) Delivers Statistically Significant Composite ALP Normalization in Phase 3 IDEAL Trial in Primary Biliary Cholangitis (PBC)

Gilead Sciences Transcript: Bernstein 42nd Annual Strategic Decisions Conference

May 28, 2026, 11:00 AM EDT - 2 months ago

Gilead Sciences Transcript: Bernstein 42nd Annual Strategic Decisions Conference

Phase 3 ASSURE Interim Data: Majority of People in the Study with ALP 1–1.67×ULN Achieved High and Sustained Composite ALP Normalization at 24 Months with Gilead's Livdelzi (Seladelpar)

May 27, 2026, 2:00 AM EDT - 2 months ago

Phase 3 ASSURE Interim Data: Majority of People in the Study with ALP 1–1.67×ULN Achieved High and Sustained Composite ALP Normalization at 24 Months with Gilead's Livdelzi (Seladelpar)

US FDA approves Gilead's drug for deadly liver infection

May 22, 2026, 2:06 PM EDT - 2 months ago

US FDA approves Gilead's drug for deadly liver infection

FDA Grants Accelerated Approval to Gilead's Hepcludex® (bulevirtide-gmod), the First and Only Approved Treatment for Chronic Hepatitis Delta Virus (HDV)

May 22, 2026, 2:00 PM EDT - 2 months ago

FDA Grants Accelerated Approval to Gilead's Hepcludex® (bulevirtide-gmod), the First and Only Approved Treatment for Chronic Hepatitis Delta Virus (HDV)

HDV

Gilead Receives CHMP Positive Opinion for Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer for Patients Not Candidates for PD-(L)1 Inhibitors

May 22, 2026, 7:47 AM EDT - 2 months ago

Gilead Receives CHMP Positive Opinion for Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer for Patients Not Candidates for PD-(L)1 Inhibitors

L

New ASCO and EHA 2026 Data Demonstrate Gilead and Kite's Momentum Across Antibody-Drug Conjugates and Cell Therapy in Oncology

May 21, 2026, 5:00 PM EDT - 2 months ago

New ASCO and EHA 2026 Data Demonstrate Gilead and Kite's Momentum Across Antibody-Drug Conjugates and Cell Therapy in Oncology

Gilead Sciences Completes Acquisition of Tubulis Further Strengthening Oncology Portfolio

May 21, 2026, 9:30 AM EDT - 2 months ago

Gilead Sciences Completes Acquisition of Tubulis Further Strengthening Oncology Portfolio

Gilead Sciences and World Health Organization Expand Collaboration to Help Eliminate Visceral Leishmaniasis, a Fatal Parasitic Disease

May 21, 2026, 3:30 AM EDT - 2 months ago

Gilead Sciences and World Health Organization Expand Collaboration to Help Eliminate Visceral Leishmaniasis, a Fatal Parasitic Disease

Gilead Sciences Transcript: RBC Capital Markets Global Healthcare Conference 2026

May 19, 2026, 11:00 AM EDT - 2 months ago

Gilead Sciences Transcript: RBC Capital Markets Global Healthcare Conference 2026

Gilead Prices $3 Billion of Senior Unsecured Notes

May 14, 2026, 9:21 PM EDT - 2 months ago

Gilead Prices $3 Billion of Senior Unsecured Notes

Gilead to Present New Data Advancing Care in PBC and Viral Hepatitis at EASL 2026

May 13, 2026, 8:30 AM EDT - 3 months ago

Gilead to Present New Data Advancing Care in PBC and Viral Hepatitis at EASL 2026

Gilead Sciences Transcript: Bank of America Global Healthcare Conference 2026

May 12, 2026, 5:20 PM EDT - 3 months ago

Gilead Sciences Transcript: Bank of America Global Healthcare Conference 2026

Gilead Sciences Expects Loss This Year on Acquired R&D Expenses

May 7, 2026, 4:39 PM EDT - 3 months ago

Gilead Sciences Expects Loss This Year on Acquired R&D Expenses

Gilead Sciences Earnings Call Transcript: Q1 2026

May 7, 2026, 4:30 PM EDT - 3 months ago

Gilead Sciences Earnings Call Transcript: Q1 2026

Gilead Sciences Slides: Q1 2026

May 7, 2026, 4:30 PM EDT - 3 months ago

Gilead Sciences Slides: Q1 2026

Gilead Sciences Earnings release: Q1 2026

May 7, 2026, 4:30 PM EDT - 3 months ago

Gilead Sciences Earnings release: Q1 2026

Gilead Sciences Quarterly report: Q1 2026

May 7, 2026, 4:30 PM EDT - 3 months ago

Gilead Sciences Quarterly report: Q1 2026

Gilead raises 2026 sales forecast, cuts profit outlook due to acquisitions

May 7, 2026, 4:05 PM EDT - 3 months ago

Gilead raises 2026 sales forecast, cuts profit outlook due to acquisitions

Gilead Sciences Announces First Quarter Financial Results

May 7, 2026, 4:01 PM EDT - 3 months ago

Gilead Sciences Announces First Quarter Financial Results

Gilead Sciences Slides: Investor presentation

May 7, 2026, 7:00 AM EDT - 3 months ago

Gilead Sciences Slides: Investor presentation

Gilead's Earnings Skyrocket as Florida's AIDS Drug Program Falters, says AHF

May 5, 2026, 2:40 PM EDT - 3 months ago

Gilead's Earnings Skyrocket as Florida's AIDS Drug Program Falters, says AHF

Focus: Use of Gilead's HIV prevention shot rises, but US insurance gaps remain

May 5, 2026, 6:01 AM EDT - 3 months ago

Focus: Use of Gilead's HIV prevention shot rises, but US insurance gaps remain

Can You Sue A Drug Company For Not Inventing Faster?

May 4, 2026, 5:15 AM EDT - 3 months ago

Can You Sue A Drug Company For Not Inventing Faster?

Big Pharma M&A set for mega year as patent expiries drive deal urgency

May 1, 2026, 10:03 AM EDT - 3 months ago

Big Pharma M&A set for mega year as patent expiries drive deal urgency

ABBV BMY GSK LLY

Gilead Sciences to Present at Upcoming Second Quarter 2026 Investor Conferences

May 1, 2026, 6:00 AM EDT - 3 months ago

Gilead Sciences to Present at Upcoming Second Quarter 2026 Investor Conferences

Gilead Sciences Transcript: AGM 2026

Apr 30, 2026, 1:00 PM EDT - 3 months ago

Gilead Sciences Transcript: AGM 2026

U.S. FDA Grants Priority Review of New Drug Application for Gilead's Once-Daily HIV Treatment of Bictegravir Plus Lenacapavir

Apr 29, 2026, 8:30 AM EDT - 3 months ago

U.S. FDA Grants Priority Review of New Drug Application for Gilead's Once-Daily HIV Treatment of Bictegravir Plus Lenacapavir

Gilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-cel

Apr 28, 2026, 8:45 AM EDT - 3 months ago

Gilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-cel

ACLX

AHF's Gilead Shareholder Resolution Seeks Transparency on Patent Exclusivities

Apr 27, 2026, 6:15 PM EDT - 3 months ago

AHF's Gilead Shareholder Resolution Seeks Transparency on Patent Exclusivities

Gilead Sciences to Release First Quarter 2026 Financial Results on Thursday, May 7, 2026

Apr 22, 2026, 4:05 PM EDT - 3 months ago

Gilead Sciences to Release First Quarter 2026 Financial Results on Thursday, May 7, 2026

Gilead Receives All Required Regulatory Approvals for the Acquisition of Arcellx and Extends Tender Offer

Apr 17, 2026, 8:30 AM EDT - 3 months ago

Gilead Receives All Required Regulatory Approvals for the Acquisition of Arcellx and Extends Tender Offer

PEPFAR and The Global Fund Make Additional Investment in Gilead's Lenacapavir for HIV Prevention to Further Expand Access

Apr 14, 2026, 12:00 PM EDT - 4 months ago

PEPFAR and The Global Fund Make Additional Investment in Gilead's Lenacapavir for HIV Prevention to Further Expand Access

imjustjimmymoore
imjustjimmymoore Aug. 5 at 11:29 PM
$CAPR $GILD $XRP.X $BTC.X $LMT http://GitHub.com/jimmymoore888/stet
1 · Reply
Quantumup
Quantumup Aug. 5 at 8:22 PM
Stifel🏁 $LYEL Buy; PT $36 and said -- We believe Rondecabtagene autoleucel (Ronde-cel) is a best-in-class, dual-targeting CD19/CD20 autologous CAR T-cell therapy yielding improved clinical outcomes vs. standard-of-care CD19-targeting CAR T-cell therapy in relapsed/refractory DLBCL. $GILD ACLX IOVA $LEGN NVS ALLO AUTL Here's what else Stifel said in its initiation report: https://x.com/Quantumup1/status/2085098840516870341?s=20
1 · Reply
FibQuants
FibQuants Aug. 5 at 5:53 PM
$GILD is showing strong momentum in HIV prevention. Yeztugo’s launch is driving major revenue growth, and early user retention looks encouraging. The market will be watching whether this adoption can stay durable over time.
0 · Reply
Estimize
Estimize Aug. 5 at 5:03 PM
$GILD reported -6.75 EPS and 7,803 revenue for Q2. http://www.estimize.com/intro/gild?chart=historical&metric_name=eps&utm_content=GILD&utm
0 · Reply
ShinnosukeNohara
ShinnosukeNohara Aug. 5 at 4:16 PM
$GILD shorties destroy it pls🙂
0 · Reply
PFElinepfrenzy1990
PFElinepfrenzy1990 Aug. 5 at 3:56 PM
$GILD - Praise ben’t
0 · Reply
shoagh12
shoagh12 Aug. 5 at 3:48 PM
$GILD
0 · Reply
GreenEnergy7B
GreenEnergy7B Aug. 5 at 3:15 PM
$ALT GLP1 Glucagon is a hot topic these days Jefferies: - "AUD crown with strongest-ever efficiacy" - " Pemvi exceeded our phs2 bull case" - "Delivering best in class AUD efficiacy" Best strategic fit would be: $NVO $PFE $SNY $GILD
0 · Reply
Snptrader
Snptrader Aug. 5 at 2:16 PM
$CMMB starting to trade like we may have another player interested here. $GILD is that you?
0 · Reply
DefenseMania
DefenseMania Aug. 5 at 1:44 PM
$AMGN $GILD $KTOS 😉💰💰💰
1 · Reply
Reanimated666
Reanimated666 Aug. 5 at 1:26 PM
$GILD Not a good quarter why is this up?
0 · Reply
Dachshundtrader
Dachshundtrader Aug. 5 at 5:40 AM
$ASMB So... no HSV update from $GILD. Disappointing? Maybe. Meaningful? Not necessarily. For a company the size of $GILD, an early-stage HSV program simply isn't earnings-call material. The spotlight now shifts back to $ASMB.
1 · Reply
TNNStockAnalysisNews
TNNStockAnalysisNews Aug. 5 at 2:56 AM
Stocks to Watch Tomorrow, Aug 5, 2026 : $LCID Post-Earnings Reaction — Day 1 Under New CEO on Display $GME Ryan Cohen Is Trying to Buy eBay — and the Stock Is Watching $GILD Post-Earnings Reaction Day $AMIX Day 2 After a 386% Explosion — What Comes Next? The Friday NFP Positioning: Already Starting Wednesday https://truthsandnews.com/markets/10-top-stocks-to-watch-tomorrow-aug-5-2026-asts-sls
1 · Reply
EarningsInsider
EarningsInsider Aug. 4 at 9:47 PM
https://www.marketbeat.com/earnings/reports/2026-8-4-gilead-sciences-inc-stock/ $GILD Gilead Sciences Earnings Transcript
0 · Reply
PFElinepfrenzy1990
PFElinepfrenzy1990 Aug. 4 at 8:44 PM
$GILD - Nice. Still a wee bit down from my average. But nice.
1 · Reply
TradeX_
TradeX_ Aug. 4 at 8:39 PM
$GILD listening
0 · Reply
AcceleratorModel
AcceleratorModel Aug. 4 at 8:22 PM
$GILD fuck I sold 138 , was tryna set a stop loss lmaooo
2 · Reply
StocktwitsEarnings
StocktwitsEarnings Aug. 4 at 8:12 PM
$GILD Q2 '26 Earnings Results & Recap • Reported GAAP EPS of -$8.45 down -638.22% YoY • Reported revenue of $7.8B up 10.18% YoY • Gilead Sciences, Inc. now expects full year 2026 product sales between $30.1 billion and $30.4 billion, with diluted loss per share between $(3.75) and $(3.40) and non-GAAP diluted loss per share between $(0.65) and $(0.30).
0 · Reply
focafoca99
focafoca99 Aug. 4 at 8:11 PM
$GILD released its Q2 2026 earnings, reporting results for the quarter ended June 30, 2026. https://www.rapidticker.com/news/gild-sec-filing-8-k-0f7532
0 · Reply
smartkarma
smartkarma Aug. 4 at 8:04 PM
📈 Earnings Alert $GILD - Gilead 2Q Adj Loss per Share $6.75, Est. Loss/Shr $7.17: ∙ Adj loss per share $6.75 vs. EPS $2.01 y/y, est loss/shr $7.17 ∙ Revenue $7.80b, +10% y/y, est $7.4b ∙ Product sales $7.63b, +8.1% y/y, est $7.37b https://www.smartkarma.com/entities/gilead-sciences-inc
0 · Reply
DefenseMania
DefenseMania Aug. 4 at 6:39 PM
$AMGN $GILD expecting some good reports AH 🚀🚀🚀as well as $KTOS
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Aug. 4 at 6:21 PM
$SLS Just saw a "long" investor saying they'd be happy with a $50 Per Share Buyout ... PEOPLE here have been Conditioned. Don't Get Short Conned. Do the Math... SLS009 is already worth Half that - right now Based on the $GILD Comp for Magro $5B for P1B AML-MR Data that was Inferior to SLS009 P2Expansion Data Published at ASH... and Just the GPS CR2/3 Market alone is worth $100++ Per Share DO THE MATH
3 · Reply